For research use only. Not for therapeutic Use.
Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM)[1].
Bezuclastinib (25 mg/kg, p.o., 3 days) shows a brain:plasma ratio of 0.07 in rats[2].
Pharmacokinetic Analysis in Rats[2]
Route
Dose (mg/kg)
t1/2 (h)
Cmax (ng/mL)
AUClast (h*ng/mL)
p.o.
25
2.8
2592±364
21509±2558
Catalog Number | I045117 |
CAS Number | 1616385-51-3 |
Synonyms | 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide |
Purity | ≥95% |
InChI | InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24) |
InChIKey | NVSHVYGIYPBTEZ-UHFFFAOYSA-N |
SMILES | CC1=C(NN=C1C(=O)NC2=CN=C3C(=C2)C=C(N3)C4=CC=CC=C4)C |